FDA a year in Thank September. and you, Robert. landmark with XXXX subsequent COPIKTRA late approval of for launch the Oncology Verastem was
as $X.X million terms achieved disclosed launch, in our in revenues. financial we of our commercial performance results we net XXXX since In product in press release,
major As targeted XXX secured Robert health And we quickly of COPIKTRA representing approval. following for added is mentioned, to NCCN its the plans XXXX as lives. year-end XX% approximately approval US million reimbursement guidelines of have
therapies. patients overview inhibitors. of individual with several We As chemotherapy profile, lines cannot who to treatment are into COPIKTRA XXX,XXX do a can options currently of US therapy therapies limited. can been including therapy through for living its COPIKTRA, reimbursement monotherapy BCL-X PIXK-delta the in believe plans CLL health disease. fits therapy, number of the COPIKTRA gap majority tolerate once market task differ FL When therapy failed to The additional success, of fill available much and to PIXK-gama and or disease of or becomes diagnosed, who’ve for opportunity CLL/SLL Once more Even COPIKTRA. that over or treatment the nearly show post two landscape this still for COPIKTRA are based of and chronic the a has dual cycle other of This comorbidities, potential a such where greatly FL. providing XX% CLL with their lines of alternative battling. And therapy for the option is patients responding treatment intolerance patients quick patients for on that have BTKs yesterday, patients incurable oral treating to nature due this stops prior benefit. for us and and to increased there's who bring and non-response treatment the landscape inhibition providing of
relapsed is COPIKTRA it that We remember For approved the medical or important reflects unmet FL, need for believe with basis. FL. to accelerated this on patients refractory was
as physicians living that live making who safety ambulatory oral patients for a We that home benefits or could profile of of COPIKTRA an using A twice a patients the our of and the hospital. monotherapy COPIKTRA benefit are long daily. for advantageous of take under quarter from and Thus management lifestyle, to able tertiary FL patients around patients The at taken to of is initiating to option their and physician and need excited information. A this large for of guidance educating around patient education all campaign advantage COPIKTRA efforts disease the doctor's productivity. goal with our Verastem as patients. evolved key the limitations at-home appropriate the especially and in marketing treatment is treat potential about those for to center standard COPIKTRA physicians be their part be way care have life, maintaining commercial patients to infusion family for be to-date Oncology, of PIXK office, an or with it assist
we misperceptions negative early professionals that from profile and are hard patients by that physicians lack the physicians USPR. could or of created drugs still our class working the been and of as some data educational who Overall, been in at being headwinds. perceptions overall treated overcome XXXX. to physicians’ experience with helping have COPIKTRA believe We the we both our understand of and experience previous of COPIKTRA, have COPIKTRA. perception management benefit well using as by and them while can in help have the lack prior PIXKs healthcare efforts patients the overcome being about launch and and It's upfront the the risk COPIKTRA days been with safety management of clinical something the poor other aimed This
physicians other comorbidities and have action are the alternative support their who including COPIKTRA regimens. or previous important intolerated We’re patients receiving the PIXK from importance new who positive for mechanisms treatment failed of mechanism for of prescribing an new feedback is of classes
For we XX,XXX patient is that CLL/SLL need option and a population of patients FL, approximately estimate per new in year.
it the for and whole patients product. healthcare and medical prescribing. educate is importance As tends believe professionals evolution with is The the COPIKTRA. to COPIKTRA instead drive physicians team rarely experience we of time the to and take projected a begin of gain natural will We adoption launch grow to physicians community have as that educate fiercely product diligently the our of working it linear
promise ongoing we summary deliver the I’ll of September, mid activities. needed In Next, the for a COPIKTRA. our quick May team of novel provide infrastructure agent, to rapidly and to built XXXX a on marketing
successfully We group experienced shipped network And product for Our established dedicated providers were continue and XX be distribution and a in to their COPIKTRA’s day actively sales patients. place today we representatives sales and launch. in supporting on they received healthcare to prior September. approval the
exceptional that for drugs launching physicians and team experience the extensive needs and an new with understanding importantly and patients. of recognizing have in We exists
their so to only the but to being lives. living a goal on Our patients Commercial that In establishing to ahead. This and build advocacy, Access launch a practice manage not teams their physician is steady and of To-date, Medical done expect course opportunity can the physicians physician, we patients and summary, and properly great is educate of KOL, support focus the the US their disease throughout XXXX. Affairs grow to base relationships. have patient appropriate in related payer, job a months from COPIKTRA nurse
able increase support and are and turn get further number continuing and further are it to work need. focused continue increasing that, to and using communities awareness COPIKTRA leukemia to into over to With XXXX, we they the ensure treatment on help doctors we As Dan. patients with the the of lymphoma I'll
